Drug rash with eosinophilia and systemic symptoms syndrome, a uncommon but fatal illness, paediatricians should be aware of: a case of 13 year old female child

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a fatal illness manifested by fever, morbilliform rash, multi systemic involvement and eosinophilic leucocytosis with about 10% mortality. Authors report DRESS syndrome in an adolescent girl due to anti-depressant and anti-psychotic which improved dramatically after withdrawal of offending drugs and starting of steroids

Download Full-text

Agranulocytosis Induced by Proton Pump Inhibitors; Bevacizumab-Induced Oral Mucositis in Background of Cutaneous Plaque-Type Psoriasis; Amiodarone-Induced T-U Fusion; Vancomycin-Induced Thrombocytopenia without Isolation of a Drug-Dependent Antibody; Capecitabine-Induced Chest Pain Relieved by Diltiazem; Fatal Clindamycin-Induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome

Hospital Pharmacy ◽

10.1310/hpj4803-183 ◽

2013 ◽

Vol 48 (3) ◽

pp. 183-187

Author(s):

Michael A. Mancano

Keyword(s):

Chest Pain ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Oral Mucositis ◽

Dress Syndrome ◽

Plaque Type ◽

Drug Rash ◽

Drug Dependent ◽

Systemic Symptoms

Download Full-text

Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients

Open Forum Infectious Diseases ◽

10.1093/ofid/ofw130 ◽

2016 ◽

Vol 3 (3) ◽

Cited By ~ 8

Author(s):

Rannakoe J. Lehloenya ◽

Sipho Dlamini ◽

Rudzani Muloiwa ◽

Betty Kakande ◽

Mzudumile R. Ngwanya ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Clinical Management ◽

Cross Reactivity ◽

Therapeutic Trial ◽

Drug Reactions ◽

Dress Syndrome ◽

Drug Eruptions ◽

Immunodeficiency Virus ◽

Drug Rash ◽

Systemic Symptoms

Abstract Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

Download Full-text

Drug rash with eosinophilia and systemic symptoms syndrome in an adolescent - efficiency of immunoglobulin G in a corticosteroid resistant case

Srpski arhiv za celokupno lekarstvo ◽

10.2298/sarh191020087s ◽

2020 ◽

pp. 87-87

Author(s):

Andjelka Stojkovic ◽

Slobodan Jankovic ◽

Dragan Milovanovic ◽

Jasmina Djindjic ◽

Vesna Velickovic

Keyword(s):

Immunoglobulin G ◽

Concomitant Administration ◽

Absolute Number ◽

Metformin Hydrochloride ◽

Dress Syndrome ◽

Therapeutic Choice ◽

Drug Rash ◽

Systemic Symptoms ◽

Elevated Transaminases

Introduction. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome (sy) to carbamazepine has a heterogeneous clinical presentation. The aim of this report is to indicate the efficacy of immunoglobulin G in the treatment of corticosteroid resistant DRESS sy. Case outline. A adolescent suffering from epilepsy treated with carbamazepine and Na-valproate was hospitalized for fever, elevated transaminases, lymphadenopathy, splenomegaly. Every day there was an eruption of skin efflorescence. On the sixth day of hospitalization, the number of eosinophils increased to 24% (780/ml absolute number). There was no desired response to methylprednisolone during the first eight days of treatment or prednisolone during further treatment, with concomitant administration of antihistamines from day one of hospitalization, Na-valproate, metformin hydrochloride, elimination diets, and carbamazepine withdrawal. Significant clinical, hematologic and biochemical improvement occurred the day after the first dose of intravenous immunoglobulin G (IVIG). Conclusion. We point out the need to change the DRESS sy treatment recommendations in favor of the IVIG (as soon as possible, already third or fourth day of treatment) in patients in whom the treatment with corticosteroids has no effect. Until new cases of the proven role of IVIG in the treatment of DRESS sy are published, corticosteroids remain the first therapeutic choice.

Download Full-text

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin

International Journal of Dermatology ◽

10.1111/j.1365-4632.2012.05547.x ◽

2013 ◽

Vol 53 (4) ◽

pp. 490-493 ◽

Cited By ~ 8

Author(s):

Maria Jose Velasco ◽

Joseph McDermott

Keyword(s):

Dress Syndrome ◽

Drug Rash ◽

Systemic Symptoms

Download Full-text

Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report

Journal of Pharmacy Practice ◽

10.1177/0897190019866094 ◽

2019 ◽

pp. 089719001986609 ◽

Cited By ~ 1

Author(s):

Tirin Babu ◽

George Mathew Panachiyil ◽

Juny Sebastian ◽

Veeranna Shastry

Keyword(s):

Case Report ◽

Signs And Symptoms ◽

Side Effect Profile ◽

Drug Reactions ◽

Dress Syndrome ◽

First Case ◽

Drug History ◽

Drug Rash ◽

Systemic Symptoms ◽

Favorable Side Effect Profile

Cefpodoxime is a common antibiotic with a favorable side effect profile. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described with several cephalosporins but not cefpodoxime. We report the probable first case of cefpodoxime-induced DRESS syndrome in a 52-year-old female patient. In our case, the patient presented with symptoms of DRESS syndrome 16 days after initiation of cefpodoxime. This case highlights the necessity of consideration of an iatrogenic reason for presenting signs and symptoms at all times. Reinforcing the importance of taking a thorough drug history and considering drug reactions even if onset of symptoms are delayed.

Download Full-text